Exact Mass: 459.3018
Exact Mass Matches: 459.3018
Found 139 metabolites which its exact mass value is equals to given mass value 459.3018
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
(5Z)-7-[(1S,5E)-5-[(2E)-Oct-2-en-1-ylidene]-4-oxocyclopent-2-en-1-yl]hept-5-enoylcarnitine
(5Z)-7-[(1S,5E)-5-[(2E)-oct-2-en-1-ylidene]-4-oxocyclopent-2-en-1-yl]hept-5-enoylcarnitine is an acylcarnitine. More specifically, it is an (5Z)-7-[(1S,5E)-5-[(2E)-oct-2-en-1-ylidene]-4-oxocyclopent-2-en-1-yl]hept-5-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (5Z)-7-[(1S,5E)-5-[(2E)-oct-2-en-1-ylidene]-4-oxocyclopent-2-en-1-yl]hept-5-enoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (5Z)-7-[(1S,5E)-5-[(2E)-oct-2-en-1-ylidene]-4-oxocyclopent-2-en-1-yl]hept-5-enoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Ile Ile Lys Ser
Ile Ile Ser Lys
Ile Lys Ile Ser
Ile Lys Leu Ser
Ile Lys Ser Ile
Ile Lys Ser Leu
Ile Lys Thr Val
Ile Lys Val Thr
Ile Leu Lys Ser
Ile Leu Ser Lys
Ile Ser Ile Lys
Ile Ser Lys Ile
Ile Ser Lys Leu
Ile Ser Leu Lys
Ile Thr Lys Val
Ile Thr Val Lys
Ile Val Lys Thr
Ile Val Thr Lys
Lys Ile Ile Ser
Lys Ile Leu Ser
Lys Ile Ser Ile
Lys Ile Ser Leu
Lys Ile Thr Val
Lys Ile Val Thr
Lys Leu Ile Ser
Lys Leu Leu Ser
Lys Leu Ser Ile
Lys Leu Ser Leu
Lys Leu Thr Val
Lys Leu Val Thr
Lys Ser Ile Ile
Lys Ser Ile Leu
Lys Ser Leu Ile
Lys Ser Leu Leu
Lys Thr Ile Val
Lys Thr Leu Val
Lys Thr Val Ile
Lys Thr Val Leu
Lys Val Ile Thr
Lys Val Leu Thr
Lys Val Thr Ile
Lys Val Thr Leu
Leu Ile Lys Ser
Leu Ile Ser Lys
Leu Lys Ile Ser
Leu Lys Leu Ser
Leu Lys Ser Ile
Leu Lys Ser Leu
Leu Lys Thr Val
Leu Lys Val Thr
Leu Leu Lys Ser
Leu Leu Ser Lys
Leu Ser Ile Lys
Leu Ser Lys Ile
Leu Ser Lys Leu
Leu Ser Leu Lys
Leu Thr Lys Val
Leu Thr Val Lys
Leu Val Lys Thr
Leu Val Thr Lys
Ser Ile Ile Lys
Ser Ile Lys Ile
Ser Ile Lys Leu
Ser Ile Leu Lys
Ser Lys Ile Ile
Ser Lys Ile Leu
Ser Lys Leu Ile
Ser Lys Leu Leu
Ser Leu Ile Lys
Ser Leu Lys Ile
Ser Leu Lys Leu
Ser Leu Leu Lys
Thr Ile Lys Val
Thr Ile Val Lys
Thr Lys Ile Val
Thr Lys Leu Val
Thr Lys Val Ile
Thr Lys Val Leu
Thr Leu Lys Val
Thr Leu Val Lys
Thr Val Ile Lys
Thr Val Lys Ile
Thr Val Lys Leu
Thr Val Leu Lys
Val Ile Lys Thr
Val Ile Thr Lys
Val Lys Ile Thr
Val Lys Leu Thr
Val Lys Thr Ile
Val Lys Thr Leu
Val Leu Lys Thr
Val Leu Thr Lys
Val Thr Ile Lys
Val Thr Lys Ile
Val Thr Lys Leu
Val Thr Leu Lys
Vocacapsaicin
C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic
(5Z)-7-[(1S,5E)-5-[(2E)-Oct-2-en-1-ylidene]-4-oxocyclopent-2-en-1-yl]hept-5-enoylcarnitine
(9Z)-17-hydroxyoctadec-9-enoate 17-O-beta-D-glucoside
(9Z)-18-hydroxyoctadec-9-enoate 18-O-beta-D-glucoside
N-[(4S,7S,8S)-5-(cyclohexylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
N-[(4S,7R,8R)-5-(cyclohexylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
N-[(4S,7S,8R)-5-(cyclohexylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
N-[(4R,7R,8R)-5-(cyclohexylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
N-[(4R,7S,8S)-5-(cyclohexylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
N-[(4R,7S,8R)-5-(cyclohexylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
N-[(4S,7R,8S)-5-(cyclohexylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
N-[(4R,5S)-2-hydroxy-2-oxo-4-[(E)-pentadec-1-enyl]-1,3,2lambda5-dioxaphosphinan-5-yl]hexanamide
(E)-3-hydroxy-2-[[(Z)-tetradec-9-enoyl]amino]dec-4-ene-1-sulfonic acid
(E)-3-hydroxy-2-[[(Z)-tridec-9-enoyl]amino]undec-4-ene-1-sulfonic acid
(4E,8E)-3-hydroxy-2-(undecanoylamino)trideca-4,8-diene-1-sulfonic acid
(4E,8E)-2-(decanoylamino)-3-hydroxytetradeca-4,8-diene-1-sulfonic acid
(4E,8E)-2-(dodecanoylamino)-3-hydroxydodeca-4,8-diene-1-sulfonic acid
(1r,3s,3'r,3'as,4ar,5s,6's,6as,6bs,7'ar,9r,11as,11bs)-1,3,5-trihydroxy-3',6',10,11b-tetramethyl-1,2,3,3'a,4,4',4a,5,5',6,6',6a,6b,7,7',7'a,8,11a-octadecahydro-3'h-spiro[cyclohexa[a]fluorene-9,2'-furo[3,2-b]pyridin]-11-one
4-hydroxy-2,3-dimethoxy-6-(10-methoxy-3,7,9,11-tetramethyltetradeca-2,5,7,11-tetraen-1-yl)-5-methylpyridin-1-ium-1-olate
12β,27-dihydroxy solasodine β-chacotrioside
{"Ingredient_id": "HBIN000744","Ingredient_name": "12\u03b2,27-dihydroxy solasodine \u03b2-chacotrioside","Alias": "NA","Ingredient_formula": "C27H41NO5","Ingredient_Smile": "CC1C2C(CC3C2(C(CC4C3CC=C5C4(CCC(C5)O)C)O)C)OC16CCC(CN6)C(=O)O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "42184","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
alkaloid sn-c; 27-carboxylic acid
{"Ingredient_id": "HBIN015174","Ingredient_name": "alkaloid sn-c; 27-carboxylic acid","Alias": "NA","Ingredient_formula": "C27H41NO5","Ingredient_Smile": "NA","Ingredient_weight": "459.62","OB_score": "NA","CAS_id": "107484-56-0","SymMap_id": "NA","TCMID_id": "NA","TCMSP_id": "NA","TCM_ID_id": "7021","PubChem_id": "NA","DrugBank_id": "NA"}